Clinical Trial Update: AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) [Phase 3]

View source ↗

Summary

The Phase 3 TRINOVA-2 trial of trebananib (AMG 386) in fallopian tube cancer, ovarian cancer, and primary peritoneal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• AMG-386 (trebananib)

Snippet

Sponsor: Amgen | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Status: TERMINATED